Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 5/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 6/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264981 | 1.00 | PANK3 (0.39) | PANK3MCHR1MLYCDDAOPOLQ | |
| SCHEMBL264979 | 1.00 | PANK3 (0.39) | PANK3MCHR1MLYCDDAOPOLQ | |
| SCHEMBL264232 | 0.90 | ALDH1A1 (0.36) | MCHR1MLYCDDAOPOLQPOLB | |
| SCHEMBL264230 | 0.90 | ALDH1A1 (0.36) | MCHR1MLYCDDAOPOLQPOLB | |
| SCHEMBL264231 | 0.90 | ALDH1A1 (0.36) | MCHR1MLYCDDAOPOLQPOLB | |
| SCHEMBL272337 | 0.88 | DAO (0.35) | MCHR1MLYCDDAOPOLQHCRTR1 | |
| SCHEMBL265925 | 0.87 | POLQ (0.37) | MLYCDDAOPOLQ | |
| SCHEMBL265924 | 0.87 | POLQ (0.37) | MLYCDDAOPOLQ | |
| SCHEMBL265923 | 0.87 | POLQ (0.37) | MLYCDDAOPOLQ | |
| SCHEMBL266187 | 0.87 | DAO (0.36) | MCHR1DAOPOLQHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2297102-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | PANK3 4601/4885MCHR1 23/4885MLYCD 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.